[EN] IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS [FR] DERIVES D'IMIDAZOPYRIDINE ET D'IMIDAZOPYRIMIDINE EN TANT QU'AGENTS ANTIBACTERIENS
[EN] IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS [FR] DERIVES D'IMIDAZOPYRIDINE ET D'IMIDAZOPYRIMIDINE EN TANT QU'AGENTS ANTIBACTERIENS
New Catalysts for Suzuki−Miyaura Coupling Reactions of Heteroatom-Substituted Heteroaryl Chlorides
作者:Anil S. Guram、Xiang Wang、Emilio E. Bunel、Margaret M. Faul、Robert D. Larsen、Michael J. Martinelli
DOI:10.1021/jo070341w
日期:2007.7.1
PdCl2PR2(Ph-R‘)}2 complexes, readily prepared from commercial reagents, exhibit unique efficiency as catalysts for the Suzuki−Miyauracoupling reactions of a variety of heteroatom-substituted heteroarylchlorides with a diverse range of aryl/heteroaryl boronic acids. The coupling reactions catalyzed by the new complexes exhibit high product yields (88−99%) and high catalyst turnover numbers (up to
IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS
申请人:Sciotti Richard John
公开号:US20090275577A1
公开(公告)日:2009-11-05
Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.
Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.
IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
申请人:Marmsater Fredrik P.
公开号:US20100144751A1
公开(公告)日:2010-06-10
Compounds of Formula (I): are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class (3) and class (5) receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.
The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water-soluble, non-peptidic oligomer.